Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiaries, Hubei Tian Sheng Pharmaceutical Co., Ltd. and Hunan Tian Sheng Pharmaceutical Co., Ltd., participated in the procurement of drugs including Dexamethasone in Guangdong Province, with several products proposed for selection in the upcoming procurement process [1] Group 1: Company Participation - Hubei Tian Sheng and Hunan Tian Sheng participated in the Guangdong Alliance procurement for Dexamethasone and other drugs [1] - The Guangdong Provincial Drug Trading Center published the proposed selection results for the procurement on October 10, 2025 [1] Group 2: Selected Products - Hubei Tian Sheng's products proposed for selection include: - Concentrated Sodium Chloride Injection - Clindamycin Hydrochloride Injection - Glucose Injection - Sodium Chloride Injection [1] - Hunan Tian Sheng's products proposed for selection include: - Cefoperazone Injection - Cefazolin Sodium Injection [1]

Core Viewpoint - ST Tian Sheng's subsidiaries, Hubei Tian Sheng and Hunan Tian Sheng, have participated in the procurement process for various pharmaceutical products, which may enhance their market presence and brand influence [1] Group 1: Procurement Participation - Hubei Tian Sheng and Hunan Tian Sheng are involved in the Guangdong Alliance procurement for drugs including concentrated sodium chloride injection, clindamycin hydrochloride injection, glucose injection, sodium chloride injection, and injectable cefoperazone and cefazolin sodium [1] Group 2: Potential Impact - The selection of these products for procurement is expected to expand the sales range and increase market share [1] - However, it is important to note that the procurement contracts have not yet been signed, leading to uncertainty regarding the subsequent impact on the company [1]

Group 1 - The Guangdong Provincial Drug Administration announced that the sodium chloride injection produced by Yangzhou Zhongbao Pharmaceutical Co., Ltd. failed quality inspection due to non-compliance with pH value standards [1][2] - The specific batch number of the non-compliant product is 324102601, and it was tested by the Food and Drug Inspection and Testing Center of Foshan City [2] - The company is required to take risk control measures such as suspending sales, recalling the product, and conducting investigations into the reasons for non-compliance [2] Group 2 - Yangzhou Zhongbao Pharmaceutical Co., Ltd. was established in 1976 and specializes in innovative pharmaceuticals focusing on cardiovascular and chronic respiratory systems [3] - The company is recognized as a national high-tech enterprise and has a comprehensive R&D platform from drug discovery to post-marketing evaluation [3] - It possesses first-class production equipment that meets GMP standards and has established a complete management system for R&D, quality, and production [3]